TrialsgrambetaRCTs are beautiful

POST-2

2016

Prevention of Syncope Trial 2

In 210 patients with recurrent vasovagal syncope, fludrocortisone did not significantly reduce the first recurrence of syncope over one year compared with placebo, although a benefit emerged once the dose had been stabilised.

Result

Efficacy: Time to first recurrence of syncope over 1 yearHR 0.69 (95% CI 0.46-1.03) · P = 0.069

Below 1 favours fludrocortisone, above 1 favours placebo.

Also reported: The prespecified 40 % relative risk reduction was not met. Restricted to the period after dose stabilisation, HR 0.51 (95 % CI 0.28–0.89; p=0.019).

Original publication
Subtopic
Vasovagal syncope
Design
Double-blind, placebo-controlled RCT
Relevance
Supporting: context rather than must-know.
Source
Sheldon R, Raj SR, Rose MS, et al. J Am Coll Cardiol. 2016;68(1):1-9.doi 10.1016/j.jacc.2016.04.030

Discussion & critique

It formally missed its primary endpoint and the supportive analyses are post hoc, so the effect is fragile. It is nonetheless the largest randomised evidence for fludrocortisone and underpins its class-IIb place in young patients with low blood pressure.